Is Heron Therapeuti (HRTX) overvalued? · $332.6M cap
Heron Therapeuti (HRTX) is a biotechnology company listed on US.
This page asks whether Heron Therapeuti (HRTX) looks expensive on cached numbers — not a short thesis.
No cached income statement for HRTX, so there is no earnings base to call rich or cheap.
HRTX currently screens at market cap $332.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HRTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HRTX stock page for the full model, not this heading.
Not investment advice.